Dexcom said its Q3 2024 revenue was $994.2 million, up 2% from $975.0 million a year earlier. U.S. revenue fell 2% to $701.9 million, while international revenue rose 12% to $292.3 million.

1. 01

   Dexcom said its Q3 2024 revenue was $994.2 million, up 2% from $975.0 million a year earlier. U.S. revenue fell 2% to $701.9 million, while international revenue rose 12% to $292.3 million.

2. 02

   The company said its GAAP operating income for Q3 was $152.0 million (15.3% of revenue), and its non-GAAP operating income was $212.0 million (21.3% of reported revenue). GAAP net income was $134.6 million, or $0.34 per diluted share.

3. 03

   The company reaffirmed its full-year 2024 outlook, calling for revenue of approximately $4.00 to 4.05 billion (11 to 13% organic growth), a non-GAAP gross profit margin of approximately 63%, and a non-GAAP operating margin of approximately 20%.

4. 04

   The company said it held $2.49 billion in cash, cash equivalents and marketable securities as of September 30, 2024, and its revolving credit facility was not drawn. It said it executed a $750 million share repurchase program in Q3.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.